Prognostic role of microRNA-210 in various carcinomas: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 9, 2015, Pages 15283-15289

  Xie, Xuejiao ^a   Wu, Wenhong ^a   Liang, Ludong ^a   Han, Shuai ^a   Chen, Ting ^b   Pan, Shangling ^c   Xue, Meijuan ^a   Li, Shikang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI TEACHERS EDUCATION UNIVERSITY   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Meta analysis; miR 210; Prognosis

Indexed keywords

MICRORNA 210; TUMOR MARKER;

ARTICLE; BIBLIOGRAPHIC DATABASE; BREAST CARCINOMA; CANCER PROGNOSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; GENE EXPRESSION; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; META ANALYSIS (TOPIC); OSTEOSARCOMA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGRESSIVE-FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL;

EID: 84946546850     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Lu S, Wang S, Geng S, Ma S, Liang Z and Jiao B. Increased expression of microRNA-17 predicts poor prognosis in human glioma. J Biomed Biotechnol 2012; 2012: 970761.
3. Povey S, Lovering R, Bruford E, Wright M, Lush M and Wain H. The HUGO Gene Nomenclature Committee (HGNC). Hum Genet 2001; 109: 678-680.
4. McCormick R, Buffa FM, Ragoussis J and Harris AL. The role of hypoxia regulated microRNAs in cancer. Curr Top Microbiol Immunol 2010; 345: 47-70.
5. Chan SY and Loscalzo J. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 2010; 9: 1072-1083.
6. Chan YC, Banerjee J, Choi SY and Sen CK. miR- 210: the master hypoxamir. Microcirculation 2012; 19: 215-223.
7. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM and Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008; 14: 1340-1348.
8. Rothe F, Ignatiadis M, Chaboteaux C, Haibe- Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart M and Sotiriou C. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011; 6: e20980.
9. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K and Croce CM. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 2012; 109: 3024- 3029.
10. Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN. Micro- RNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011; 10: 507-517.
11. Cai H, Lin L, Cai H, Tang M and Wang Z. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol 2013; 30: 499.
12. Greither T, Wurl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschlager C, Holzhausen HJ, Wach S, Eckert AW and Taubert H. Expression of microRNA 210 associates with poor survival and age of tumor onset of softtissue sarcoma patients. Int J Cancer 2012; 130: 1230-1235.
13. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol 2010; 5: 1755-63.
14. Osugi J, Kimura Y, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, Yonechi A, Hoshino M, Higuchi M, Shio Y, Suzuki H, Gotoh M. Prognostic impact of hypoxia-inducible microrna- 210 in patients with lung adenocarcinoma. J Oncol 2015; 2015: 316745.
15. CJ E, K C, AS B and M R. Differential microrna expression in colorectal cancer patients presenting with synchronous hepatic metastases. Modern Pathology 2013; 1.
16. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB and Gleadle JM. The VHL-dependent regulation of microRNAs in renal cancer. BMC Med 2010; 8: 64.
17. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, Selby PJ, Banks RE and Harris AL. miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer 2013; 108: 1133-1142.
18. Qiu S, Lin S, Hu D, Feng Y, Tan Y and Peng Y. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med 2013; 11: 10.
19. Lai NS, Dong QS, Ding H, Miao ZL and Lin YC. MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. J Clin Neurosci 2014; 21: 755-760.
20. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P and Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126: 73- 80.
21. Gee HE, Camps C, Buffa FM, Patiar S, Winter SC, Betts G, Homer J, Corbridge R, Cox G, West CM, Ragoussis J and Harris AL. hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer. Cancer 2010; 116: 2148-2158.
22. Toyama T, Kondo N, Endo Y, Sugiura H, Yoshimoto N, Iwasa M, Takahashi S, Fujii Y and Yamashita H. High expression of microRNA- 210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol 2012; 42: 256-263.
23. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 2000; 283: 2008-2012.
24. Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
25. Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
26. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629- 634.
27. Fu X, Han Y, Wu Y, Zhu X, Lu X, Mao F, Wang X, He X, Zhao Y and Zhao Y. Prognostic role of microRNA- 21 in various carcinomas: a systematic review and meta-analysis. Eur J Clin Invest 2011; 41: 1245-1253.
28. He J, Zhang F, Wu Y, Zhang W, Zhu X, He X, Zhao Y, Zhang W and Zhao Y. Prognostic role of microRNA-155 in various carcinomas: results from a meta-analysis. Dis Markers 2013; 34: 379-386.
29. Hong L, Yang J, Han Y, Lu Q, Cao J and Syed L. High expression of miR-210 predicts poor survival in patients with breast cancer: a metaanalysis. Gene 2012; 507: 135-138.
30. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ and Brown PO. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006; 3: e47.
31. Guan P, Yin Z, Li X, Wu W, Zhou B. Metaanalysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res 2012; 31: 54.
32. Hayes DF, Isaacs C and Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001; 6: 375-392.
33. Shibuya H, Iinuma H, Shimada R, Horiuchi A and Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA- 155 in colorectal cancer. Oncology 2010; 79: 313-320.